Produção de anticorpos para tratamento do cancro da mama

A terapia anti-cancro baseada em anticorpos monoclonais tem vindo a ser atractiva na medida em que os anticorpos têm a capacidade de reconhecer especificamente antigénios alvo associados a cancro e de serem reconhecidos por células do sistema imunitário. Um dos antigénios que tem vindo a ser estudado é o glicano sialil-Tn (STn), presente na maioria dos carcinomas humanos e aproximadamente em 30% dos casos de cancro da mama. O objectivo geral deste trabalho foi o desenvolvimento de novos anticorpos terapêuticos contra STn. Especificamente, foi estudada a imunogenicidade de diferentes antigénios baseados em STn na produção desses anticorpos. Através da análise dos soros, verificou-se uma resposta imune com produção de anticorpos pelos murganhos imunizados, em separado, com mucina1 decorada com STn, mucinas de origem animal STn+ e lisados celulares STn+. Contrariamente, a imunização com STn associado a treonina ou poliacrilamida não desencadeou nenhuma resposta imunológica. Assim, percebeu-se que o STn é muito pouco imunogénico, e que a imunogenicidade deste depende do seu acoplamento a proteínas (mucinas) e da densidade do glicano a decorar as mesmas. Os sobrenadantes da cultura dos hibridomas obtidos pela fusão celular foram analisados por citometria de fluxo. Embora, se esperasse obter hibridomas produtores de anticorpos anti-STn, isto não se verificou. Uma das hipóteses levantadas está relacionada com a tolerância imunológica induzida por este antigénio, tal como verificado anteriormente pelo nosso e outros grupos de investigação. Assim, novas imunizações estão a ser realizadas com alterações relevantes no protocolo. A segunda parte deste trabalho consistiu na criação (transdução lentiviral) e análise (citometria de fluxo e RT-PCR) da linha celular fluorescente MCF-7/GFP STn+, que permitirá analisar o mecanismo de acção dos anticorpos anti-STn futuramente produzidos. A realização deste trabalho permitiu optimizar diversas técnicas e passos-chave importantes para o desenvolvimento de anticorpos terapêuticos anti-STn para cancro da mama ou outros cancros que expressem STn.

A CMMI-compliant requirements management and development process

Requirements Engineering has been acknowledged an essential discipline for Software Quality. Poorly-defined processes for eliciting, analyzing, specifying and validating requirements can lead to unclear issues or misunderstandings on business needs and project’s scope. These typically result in customers’ non-satisfaction with either the products’ quality or the increase of the project’s budget and duration. Maturity models allow an organization to measure the quality of its processes and improve them according to an evolutionary path based on levels. The Capability Maturity Model Integration (CMMI) addresses the aforementioned Requirements Engineering issues. CMMI defines a set of best practices for process improvement that are divided into several process areas. Requirements Management and Requirements Development are the process areas concerned with Requirements Engineering maturity. Altran Portugal is a consulting company concerned with the quality of its software. In 2012, the Solution Center department has developed and applied successfully a set of processes aligned with CMMI-DEV v1.3, what granted them a Level 2 maturity certification. For 2015, they defined an organizational goal of addressing CMMI-DEV maturity level 3. This MSc dissertation is part of this organization effort. In particular, it is concerned with the required process areas that address the activities of Requirements Engineering. Our main goal is to contribute for the development of Altran’s internal engineering processes to conform to the guidelines of the Requirements Development process area. Throughout this dissertation, we started with an evaluation method based on CMMI and conducted a compliance assessment of Altran’s current processes. This allowed demonstrating their alignment with the CMMI Requirements Management process area and to highlight the improvements needed to conform to the Requirements Development process area. Based on the study of alternative solutions for the gaps found, we proposed a new Requirements Management and Development process that was later validated using three different approaches. The main contribution of this dissertation is the new process developed for Altran Portugal. However, given that studies on these topics are not abundant in the literature, we also expect to contribute with useful evidences to the existing body of knowledge with a survey on CMMI and requirements engineering trends. Most importantly, we hope that the implementation of the proposed processes’ improvements will minimize the risks of mishandled requirements, increasing Altran’s performance and taking them one step further to the desired maturity level.

Customer relationship management at Siemens Healthcare – a diagnosis and proposal for strategy and market segmentation

Towards a holistic perspective of CRM, this project aims to diagnose and propose a strategy and market segmentation for Siemens Healthcare. The main underlying principle is to apply a full customer-centric outlook taking own business properties into consideration while preserving Siemens Healthcare’s culture and vision. Mainly focused on market segmentation, this project goes beyond established boundaries by employing an unbiased perspective of CRM while challenging current strategy, goals, processes, tools, initiatives and KPIs. In order to promote a sustainable business excellence strategy, this project aspires to streamline CRM strategic importance and driving the company one step forward.